Susan Ruediger on Partnering to Develop CMT Gene Therapies

Video

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed a new partnership with Nationwide Children’s Hospital.

“Dr. Afrooz Rashnonejad at Nationwide Children's Hospital has found an approach that will address all of the mutations in myelin protein zero (MPZ). And she hopes that she can knock down and replace the way that that gene expresses in a way that addresses all people and all mutations of CMT1B.”

The CMT Research Foundation (CMTRF) is working to help researchers find treatments for Charcot-Marie-Tooth disease (CMT) by funding promising projects, including cell and gene therapy approaches, to address unmet needs in CMT.

The CMTRF recently signed an agreement with Nationwide Children’s Hospital and awarded a $500,000 grant to Afrooz Rashnonejad, PhD, principal investigator at Nationwide and Assistant Professor at the Ohio State University’s Department of Pediatrics in Columbus, Ohio. Rashnonejad is investigating a knock down and replace approach to silence the mutated MPZ gene and replace it with a functioning gene.

CGTLive spoke with Susan Ruediger, founder and chief mission officer, CMT Research Foundation, to learn more about the new grant and research that it is funding. She discussed the potential of the gene therapy research approach. She also discussed how such partnerships benefit the researcher, the CMTRF, and patients.

REFERENCE
CMT Research Foundation Awards Grant to Nationwide Children’s Hospital’s Dr. Afrooz Rashnonejad to Develop Gene Therapy to Cure or Alleviate CMT1B. News release CMTRF. July 18, 2022. https://cmtrf.org/nationwide-childrens-hospital-cmt1b-press-release/

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
© 2025 MJH Life Sciences

All rights reserved.